BiotechTube

Qutenza + Pregabalin

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Non-diabetic Painful Peripheral Polyneuropathy

Conditions

Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)

Trial Timeline

Jul 11, 2012 → Sep 26, 2013

NCT ID
NCT01713426

About Qutenza + Pregabalin

Qutenza + Pregabalin is a approved stage product being developed by Astellas Pharma for Non-diabetic Painful Peripheral Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01713426. Target conditions include Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI).

What happened to similar drugs?

1 of 2 similar drugs in Non-diabetic Painful Peripheral Polyneuropathy were approved

Approved (1) Terminated (0) Active (1)
✅Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved
🔄Finerenone (BAY94-8862) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01713426ApprovedCompleted

Competing Products

3 competing products in Non-diabetic Painful Peripheral Polyneuropathy

See all competitors
ProductCompanyStageHype Score
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mgAstraZenecaApproved
43
Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + RamiprilNovartisPhase 2
27
Finerenone (BAY94-8862) + PlaceboBayerPhase 3
37